Treatment of acute myeloblastic leukemia in adults: remission induction with a combination of cyclophosphamide, cytarabine and vincristine.
D000328:Adult; D000367:Age Factors; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D005260:Female; D006505:Hepatitis / Q000209:etiology; D006511:Hepatitis B Antigens; D006760:Hospitalization; D006801:Humans; D007275:Injections, Intravenous; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D009113:Muramidase / Q000097:blood; D012075:Remission, Spontaneous; D014750:Vincristine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use
D006511:Hepatitis B Antigens; D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D009113:Muramidase